01—Abstract
Summary
Summary of the 10-Q filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. reported strong revenue growth in the fourth quarter of fiscal year 2024, with a 12.8%a increase year-over-year, driven primarily by its U.S. Healthcare Solutions segment.
This growth was bolstered by significant sales of GLP-1 class products for diabetes and weight loss, as well as increased specialty product sales. Despite the revenue surge, net income attributable to Cencora, Inc. saw a decline to $488.6 millionb from $601.5 million in the prior year's comparable period, leading to a decrease in diluted earnings per share from $2.98 to $2.50.
This profitability dip can be attributed to higher operating expenses, including increased litigation and opioid-related expenses, and a decrease in gains from antitrust litigation settlements. The company also completed a significant acquisition of Retina Consultants of America (RCA) for $4.4 billionc in early January 2025, further impacting its financial position and future growth trajectory.
02—Key points
Key Highlights
- Revenue increased by 12.8% year-over-year to $81.5 billion, driven by a 13.6% increase in the U.S. Healthcare Solutions segment.
- Sales of GLP-1 class products for diabetes and weight loss contributed $3.2 billion in increased revenue.
- Net income attributable to Cencora, Inc. decreased to $488.6 million from $601.5 million in the prior year's quarter.
- Diluted earnings per share declined to $2.50 from $2.98 year-over-year.
- Operating expenses increased by 12.5%, notably due to higher litigation and opioid-related expenses compared to a credit in the prior year.
- Cencora completed the acquisition of Retina Consultants of America (RCA) for $4.4 billion in early January 2025.
- The company repurchased $385.4 million of its common stock during the quarter and increased its quarterly dividend by 8%.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Cencora, Inc. kept $0.01.
- Revenue$81.49B100.0%
- Cost of revenue−$78.93B96.9%
- Gross profit$2.56B3.1%
- Operating costs−$1.85B2.3%
- Operating income$706.3M0.9%
- Interest, other & tax−$217.7M0.3%
- Net income$488.6M0.6%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed February 5, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $81.49B$72.25B | +12.8% |
| Cost of Revenue | $78.93B$69.78B | +13.1% |
| Gross Profit | $2.56B$2.47B | +3.6% |
| SG&A Expenses | $1.47B$1.40B | +5.2% |
| Operating Expenses | $1.59B— | — |
| Operating Income | $706.25M$822.88M | −14.2% |
| Net Income | $488.60M$601.50M | −18.8% |
| EPS (Basic) | $2.52$3.01 | −16.3% |
| EPS (Diluted) | $2.50$2.98 | −16.1% |
| Shares Outstanding (Basic) | 193.76M200.08M | −3.2% |
| Shares Outstanding (Diluted) | 195.19M201.84M | −3.3% |
05—Questions
Frequently Asked Questions
What was the primary driver of Cencora's revenue growth in the quarter?
The primary driver of Cencora's revenue growth was the U.S. Healthcare Solutions segment, which saw a 13.6% increase. This growth was significantly boosted by a 53.0% increase in sales of GLP-1 class products for diabetes and weight loss, totaling $3.2 billion, and increased sales of specialty products to physician practices and health systems.
Why did Cencora's net income decrease despite higher revenues?
Despite a significant increase in revenue, Cencora's net income attributable to the company decreased from $601.5 million to $488.6 million. This was primarily due to a substantial rise in operating expenses, which grew by 12.5%. Key contributors to this increase included higher litigation and opioid-related expenses, which were a credit in the prior year, and a decrease in gains from antitrust litigation settlements.
What are the implications of the recent acquisition of Retina Consultants of America (RCA)?
Cencora acquired an 85% interest in Retina Consultants of America (RCA) for $4.4 billion in early January 2025. RCA's results will be consolidated into the U.S. Healthcare Solutions segment. This significant acquisition is expected to contribute to future growth but also involved substantial cash outlay and potential contingent consideration, impacting the company's financial position and capital structure.
How is Cencora managing its debt and liquidity following recent financing activities?
Cencora has actively managed its debt and liquidity. During the quarter, the company issued $1.8 billion in senior notes and drew on revolving credit facilities, partly to finance the RCA acquisition. It also has significant availability under its multi-currency revolving credit facility and receivables securitization facility. The company also repurchased shares and increased its dividend, demonstrating confidence in its financial position, while noting expected increases in interest expense due to new debt.
06—Continue